Excellent results form this study!
What are shareholders thoughts on only a 3 year market exclusivity impacting the valuation ?
I do expect this business to be taken over slightly before final FDA approval by a big pharma, but have concerns that 3 years may not be long enough.
It is true that the first product to market will still maintain roughly 50% of its market share in the first year out of exclusivity, however I worry this limits the value of the company from an acquisition standpoint.
Ann: SPONTAN achieves positive clinical study results, page-70
Add LTP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
-0.040(2.30%) |
Mkt cap ! $146.6M | |||
| Open | High | Low | Value | Volume |
| $1.71 | $1.76 | $1.67 | $421.0K | 247.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1009 | $1.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.71 | 3495 | 3 |
View Market Depth
| Last trade - 12.48pm 09/09/2024 (20 minute delay) ? |
| LTP (ASX) Chart |